Connect with us

Technology

Piramal Pharma Limited Announces Results for Q4 and Full-year FY26

Published

on

MUMBAI, India, April 28, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31st March 2026.

Consolidated Financial Highlights

(in ₹ Crores or as stated)

Particulars

Q4FY26

Q4FY25

YoY %

FY26

FY25

YoY %

Revenue from Operations

2,752

2,754

(0) %

8,869

9,151

(3) %

   CDMO

1,708

1,788

(4) %

4,915

5,447

(10) %

   CHG

755

705

7 %

2,703

2,633

3 %

   PCH

320

274

17 %

1,274

1,093

17 %

EBITDA

507

603

(16) %

1,135

1,580

(28) %

EBITDA Margin

18 %

22 %

13 %

17 %

PAT Before Expectational Item

167

154

9 %

(130)

91

NM

Exceptional Item1

(176)

NM

(196)

NM

PAT After Expectational Item

(9)

154

NM

(326)

91

NM

1. During the quarter, the management has recognized an impairment loss of ₹. 176Cr in relation to intangible assets under development. Based on a reassessment incorporating changes in market conditions and updated commercial viability estimates, management concluded that the probable future economic benefits from the asset are no longer expected to be adequate to justify further capital deployment.  Accordingly, the carrying amount has been written down in full.

Key Highlights

Revenue – Growth was impacted by inventory destocking, slower early-stage order inflows in H1FY26, and softer traction in inhalation anesthesia across ex‑US markets. Adjusted for inventory destocking, we delivered YoY growth in Q4 and FY26.EBITDA Margin – Despite lower revenues, impact on EBITDA was partly offset by our efforts towards cost optimization and operational excellence.Capex – US$94Mn invested in FY26 across growth and maintenance projects. Lexington and Riverview expansions on track. Seeing good customer interest.Net Debt – No increase over FY25.

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY26 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note, with clear momentum across all our businesses. The meaningful recovery in biopharma funding seen from Sep’25,  is translating into good RFP momentum and healthy pick up in order inflows in our  CDMO business. In the CHG business, the recently completed Kenalog® acquisition alongside ramp up of inhalation anesthesia sales in ex-US markets are expected to be key growth drivers. Our Consumer Healthcare business is also well positioned to sustain its growth momentum with margin improvement driven by Power Brands and rapid growth in e‑commerce.

Overall, all three businesses are well positioned to deliver growth in FY27, accompanied by accelerated growth in EBITDA and PAT.”

Key Business Highlights

Contract Development and Manufacturing Organization (CDMO):

Healthy traction in RFPs and order inflows in H2FY26 driven by stronger US biopharma funding (up YoY 75% in H2FY26, 30% in FY26) and M&A activity. (Industry Source)Overseas sites seeing rising demand from shifting customer geographical preferences and strong growth in differentiated areas such as ADC, HP API, on‑shore injectables and drug product capabilities.US$90Mn Capex on track to scale sterile injectable and payload-linker capacities at Lexington and Riverview sites.Net Promoter Score of 60 – surpassing industry average. Meaningful improvement in execution with stronger performance across key operational matrices, driven by our operational excellence initiatives.209 customer site audits in FY26 vs. 165 in FY25 — highest ever. Reflecting heightened customer engagement, deeper technical interactions, and the growing complexity of programs we support.Maintained our Best-in-Class Quality Track Record – Successfully closed 38 regulatory inspections, including 3 USFDA inspections in FY26. Continue to maintain our ‘Zero OAI’ status.

Complex Hospital Generics (CHG):

Completed Kenalog® acquisition

– Upfront consideration of US$35Mn, and contingent consideration of up to US$65Mn.
– Broadens CHG portfolio, adds revenues with minimal incremental cost, and expands presence in US, Europe & Asia Pacific.
– Niche brand with complex manufacturing process. EBITDA margins in line with CHG business.

Inhalation Anesthesia (IA) 

– Continue to maintain leadership with 47% market share – up from 45% in Mar’24. (Source:- IQVIA)
– Initiated Sevoflurane supplies from lower cost Digwal facility in select RoW markets. Expect traction to build going ahead.

Intrathecal Therapy – Maintained our #1 Rank in intrathecal Baclofen segment in the US. (Source:- IQVIA)Injectable Pain Management – Continue to work with our supplier to resolve supply constraints.

Piramal Consumer Healthcare (PCH):

Power Brands continued growth momentum with 24% YoY growth in FY26, contributing 52% to PCH sales. Little’s, Lacto Calamine, CIR, and i-range remained primary driver of growth.New Product Launches – Fewer, high‑potential product launches with better success rates. Launched 31 new products and SKU in FY26. Focus on premiumization of portfolio.E-commerce sales grew at 48% rate YoY in FY26, contributing about 27% to PCH sales. Evolve product mix toward premium offerings and high margin channel (e.g. quick commerce).Invested about 12% of PCH sales on Media and Trade Promotion in FY26. Optimizing the media mix – Social Media, Television, Influencers, etc.

Consolidated Profit and Loss Statement

(in ₹ Crores or as stated)

Particulars

Quarterly

Full-year

Q4FY26

Q4FY25

YoY  %

Q3FY26

QoQ  %

FY26

FY25

YoY  %

Revenue from Operations

2,752

2,754

(0) %

2,140

29 %

8,869

9,151

(3) %

Other Income

46

42

10 %

43

7 %

213

135

58 %

Total Income

2,798

2,796

0 %

2,183

28 %

9,082

9,286

(2) %

Material Cost

1,056

955

11 %

786

34 %

3,239

3,232

0 %

Employee Expenses

586

612

(4) %

600

(2) %

2,416

2,307

5 %

Other Expenses

650

626

4 %

558

16 %

2,293

2,167

6 %

EBITDA

507

603

(16) %

239

112 %

1,135

1,580

(28) %

Interest Expenses

83

104

(20) %

89

(7) %

341

422

(19) %

Depreciation

218

243

(10) %

213

3 %

831

816

2 %

Share of Net Profit of Associates

14

16

(16) %

10

32 %

57

73

(22) %

Profit Before Tax

219

273

(20) %

(53)

NM

20

415

(95) %

Tax

52

119

(57) %

42

22 %

150

324

(54) %

Net Profit after Tax

167

154

9 %

(95)

NM

(130)

91

NM

Exceptional item1

(176)

NM

(41)

NM

(196)

NM

Net Profit after Tax after Exceptional Item

(9)

154

NM

(136)

NM

(326)

91

NM

During the quarter, the management has recognized an impairment loss of Rs. 176Cr in relation to intangible assets under development. Based on a reassessment incorporating changes in market conditions and updated commercial viability estimates, management concluded that the probable future economic benefits from the asset are no longer expected to be adequate to justify further capital deployment.  Accordingly, the carrying amount has been written down in full.

Consolidated Balance Sheet

(in ₹ Cr.)

   Key Balance Sheet Items

As at

31-Mar-26

31-Mar-25

Total Equity

8,162

8,125

Net Debt

4,140

4,199

Total

12,302

12,324

Net Fixed Assets

9,784

9,110

    Tangible Assets

4,843

4,534

    Intangible Assets including goodwill

3,841

3,599

    CWIP (including IAUD2)

1,100

977

Net Working Capital

2,057

2,798

Other Assets3

462

416

Total Assets

12,302

12,324

2. IAUD – Intangible Assets Under Development; 3. Other Assets include Investments and Deferred Tax Assets (Net)

Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on 29th April 2026 from 9:30 AM to 10:15 AM (IST) to discuss its Q4 and full-year FY26 Results.

The dial-in details for the call are as under:

Event

Location & Time

Telephone Number

Conference call on 29th April 2026

India – 09:30 AM IST

+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)

1 800 120 1221 (Toll free number)

USA – 12:00 AM

(Eastern Time – New York)

Toll free number

18667462133

UK – 05:00 AM

(London Time)

Toll free number

08081011573

Singapore – 12:00 PM

(Singapore Time)

Toll free number

8001012045

Hong Kong – 12:00 PM

(Hong Kong Time)

Toll free number

800964448

Express Join with Diamond Pass™

Please use this link for prior registration to reduce wait time at the time of joining the call –Click here

About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 171 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit:  Piramal Pharma | LinkedIn

1. Includes one facility via PPL’s minority investment in Yapan Bio.

Logo – https://mma.prnewswire.com/media/1855206/5942698/Piramal_Pharma_Limited_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-results-for-q4-and-full-year-fy26-302756234.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Vaultzy and Miracle University Pilot Demonstrates AI-Powered Document Management for Students. Expansion Planned for California Foster Youth Programs

Published

on

By

A successful student pilot demonstrates how secure digital records and AI guidance can help them access education, employment, housing, and life opportunities

SACRAMENTO, Calif., June 19, 2026 /PRNewswire-PRWeb/ — Vaultzy, an AI-powered document management and life assistant platform, today announced the successful completion of a pilot with Miracle University, demonstrating how secure digital records and intelligent guidance can help students overcome barriers to education, employment, and economic mobility.

California State Treasurer Fiona Ma, CPA, noted, “Never expired. Never lost. Your vital documents, all in one secure place.”

For many students, particularly those facing economic hardship or life disruptions, lost identification, unavailable transcripts, and scattered paperwork can delay enrollment, employment, housing applications, financial aid, and access to public services. Vaultzy was created to address this challenge by providing a secure, user-controlled platform for lifelong document management.

Beyond document storage, Vaultzy recently launched the first version of its AI-powered Life Agent. The platform allows users to interact with their personal records and receive guidance related to major life transitions. By understanding what documents a user has available, the Life Agent can help identify requirements and next steps for education, employment, healthcare, government services, financial planning, and other important milestones.

The pilot was conducted in partnership with Miracle University, a Sacramento-based nonprofit organization dedicated to helping students who have left the traditional education system earn their high school diplomas and achieve academic and career success. The initiative focused on helping students digitize, organize, and securely manage their most important records while introducing them to emerging technologies that can support their long-term success.

“Our mission is to help students overcome barriers and unlock their full potential,” said Dr. Kadhir Raja, Founder of Miracle University. “Students need access to their documents, confidence in managing important life transitions, and guidance on what comes next. Vaultzy helps bring all of these together, empowering students to navigate education, employment, housing, and other life opportunities with greater confidence and independence.”

The pilot demonstrated the importance of giving individuals lifelong access to trusted records while providing the tools and guidance needed to use them effectively. As California State Treasurer Fiona Ma, CPA, noted, “Never expired. Never lost. Your vital documents, all in one secure place.”

Looking ahead, Vaultzy plans to continue expanding its AI-powered capabilities. “We envision a future where every individual has a trusted AI companion that not only safeguards their records but also helps guide them through life’s most important transitions,” said Avanti Ramraj, Co-Founder and Chief Product Officer of Vaultzy.

The success of the Miracle University pilot is helping inform broader discussions with educational institutions, nonprofit organizations, financial institutions, and public-sector leaders interested in modernizing how individuals manage and access trusted records while receiving guidance through important life transitions. One of the most promising opportunities is the potential application of Vaultzy within programs serving foster youth, seniors, and other underserved populations.

About Vaultzy

Vaultzy is an AI-powered document management and life assistant platform that helps individuals securely store, manage, and share important records throughout their lives. Combining secure document management, document intelligence, multilingual assistance, and agentic AI capabilities, Vaultzy is building the infrastructure for lifelong document ownership and trusted digital identity.

About Miracle University

Miracle University is a Sacramento-based nonprofit organization dedicated to helping students overcome educational barriers and achieve academic, personal, and professional success. Through mentorship, education, and community support, Miracle University equips students with the skills, confidence, and opportunities needed to transform their futures.

Media Contact
Anupriya Ramraj, Vaultzy, 1 510-255-0657, contact@vaultzy.ai, www.vaultzy.ai

Twitter, LinkedIn

View original content:https://www.prweb.com/releases/vaultzy-and-miracle-university-pilot-demonstrates-ai-powered-document-management-for-students-expansion-planned-for-california-foster-youth-programs-302805103.html

SOURCE Vaultzy

Continue Reading

Technology

Light AI Announces Closing of C$5,000,000 Secured Convertible Debenture Unit Financing

Published

on

By

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

VANCOUVER, BC, June 19, 2026 /CNW/ – Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO) (FSE: OHC) (OTCQB: OHCFF), a digital healthcare technology company focused on developing artificial intelligence (“AI”) health diagnostic solutions, is pleased to announce that it has completed its previously announced private placement of secured convertible debenture units of the Company (the “Units”) at $1,000 per Unit for aggregate gross proceeds of $5,000,000 (the “Financing”) pursuant to an investment agreement (the “Investment Agreement”) with MV Capital LP (the “Investor”).

Pursuant to the Investment Agreement, the Investor subscribed for and purchased from the Company 5,000 Units. Each Unit is comprised of (i) a 12.0% secured convertible debenture of the Company in the principal amount equal to $1,000 (each, a “Convertible Debenture”) with interest compounded quarterly and payable on the earlier of the Maturity Date (as defined hereafter), prepayment or upon conversion and maturing 24 months from the closing of the Financing (the “Maturity Date”), and (ii) 8,000 common share purchase warrants (each, a “Warrant”) exercisable for 36 months from the closing of the Financing (the “Closing Date”) to purchase one common share of the Company (each, a “Warrant Share”) at an exercise price of $0.25 per Warrant Share, subject to adjustment in certain events.

Each Convertible Debenture allows the Investor to convert the outstanding principal thereof into common shares of the Company (the “Debenture Shares”) at a price of $0.125 per Debenture Share (the “Conversion Price”) at the option of the Investor at any time prior to the earlier of (i) the Maturity Date; and (ii) the business day immediately preceding the date specified for prepayment of the Convertible Debenture, subject to acceleration in certain events. The Company may elect to pay any accrued and unpaid interest in either (i) cash, (ii) common shares of the Company (the “Common Shares”) at the Conversion Price, subject to the approval of Cboe Canada Inc. (the “Exchange”), or (iii) any combination of the foregoing. The Convertible Debentures will be secured by a security interest over all present and after-acquired property and assets of the Company.

The Investor has agreed not to convert any Convertible Debenture or exercise any Warrants if doing so would result in the Investor holding greater than 19.9% of the issued and outstanding Common Shares, without the Company obtaining the requisite approval of its shareholders and the Exchange.

The Convertible Debentures, the Warrants, the Conversion Shares and Warrant Shares are subject to a statutory hold period of four months and one day from the closing date in accordance with applicable Canadian securities laws.

The proceeds of the Financing will be used for general working capital purposes, and to support ISO 13485/QMS audit completion and Health Canada registration submission.

In connection with the Financing, the Company and the Investor have entered into an investor rights agreement (the “Investor Rights Agreement”), which includes the following key elements:

The Investor will have the right to participate in future financings of the Company to maintain its pro rata percentage of Common Shares following the completion the Financing; andThe Investor shall have the right to nominate one member to the board of directors of the Company.

The Investor Rights Agreement shall terminate on the earlier of: (i) the closing of any take-over bid of the Company, acquisition, arrangement, amalgamation, merger or other similar business combination transaction involving the Company; and (ii) the later of either of the following: (A) the date the Investor no longer maintains at least a 10% equity interest in the Company, and (B) the date on which the principal amount of the Convertible Debenture owed to the Investor is less than $250,000.

About Light AI Inc. (CBOE CA: ALGO / FSE: OHC / OTCQB: OHCFF)

Light AI Inc. is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI QuickScan™ is a technology platform which represents the next generation of patient management: it applies AI algorithms to compatible smart device images, starting with images of Strep A and anticipated expansion with other medical conditions, to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind as its computing platform includes the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective screening and diagnostic tools designed to address critical healthcare challenges.

In pre-FDA validation studies, Light AI’s algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (“GAS”). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (“RHD”), which imposes a global economic burden exceeding $1 trillion annually. Light AI’s technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI’s approach to applying AI to smart device images can be expanded to other medical conditions, as well as other areas of analysis. Light AI’s vision is to combine the Light AI QuickScan™ software platform with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

ON BEHALF OF THE COMPANY

“John R. Luna”
Chief Executive Officer
Telephone: 1-(888) 804-9459
Email: jluna@light.ai

For more information, please contact the Company at investors@light.ai or visit https://light.ai/.

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI 
X (Formerly Twitter): @lightaihealth

Forward-Looking Information:

This news release contains statements and information that, to the extent that they are not historical fact, constitute “forward-looking information” within the meaning of applicable securities legislation, including statements relating to the use of proceeds of the Financing, the anticipated appointment of a board nominee of the Investor, and the advancement of the Company’s ISO 13485/QMS audit and Health Canada registration. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, but not limited to, statements relating to the Company’s financial performance, business development, results of operations, and those listed in filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking information to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws.

SOURCE Light AI Inc.

Continue Reading

Technology

EasySpanishTax.com Launches Simple DIY Modelo 210 Filing Solution for Non-Resident Property Owners in Spain

Published

on

By

Founder Björn Ingbrant introduces a faster, easier and more affordable way for foreign property owners to meet their Spanish tax obligations online.

MANILVA, Spain, June 19, 2026 /PRNewswire/ — The EasySpanishTax.com has launched a practical online solution designed to help non-resident property owners in Spain file their annual Modelo 210 tax declaration quickly, easily and at a lower cost.

Created by founder and developer Björn Ingbrant, EasySpanishTax.com is built specifically for international property owners who want to manage their Spanish non-resident tax obligations without unnecessary complexity, delays or high professional fees.

Modelo 210 is a tax declaration required for non-resident property owners in Spain, including owners who use their property privately, rent it out, or keep it as a holiday home. For many foreign owners, the process has traditionally felt difficult and confusing, often requiring external assistance.

EasySpanishTax.com has been developed to change that.

“Many non-resident owners are fully capable of completing their Modelo 210 declaration themselves when the process is explained clearly,” says Björn Ingbrant, founder of EasySpanishTax.com. “Our goal is to make Spanish property tax filing simple, transparent and affordable.”

The platform guides users through the filing process step by step. Property owners enter the required information online, create an account and can manage their declarations in one secure place. The service is designed to save time, reduce costs and make annual tax filing more accessible for owners living abroad.

According to Ingbrant, the need for a simplified solution became clear after years of working with international property owners in Spain.

“Many owners were paying high fees every year for a declaration that could be made much easier with the right digital system,” he explains. “We wanted to create a platform where the owner remains in control, the process is faster, and the cost is reasonable.”

In addition to Modelo 210 filing, EasySpanishTax.com has introduced a property document storage feature for registered users. This allows clients to upload and store important property documents directly in their account, including title deeds, NIE certificates, passport copies, home insurance policies, water and electricity contracts, IBI tax receipts, community documents and previous tax declarations.

The new feature transforms the platform into more than a tax filing service. It gives property owners a central digital hub for managing key documents related to their Spanish property.

“For non-resident owners, having all property documents in one place is extremely useful,” says Ingbrant. “Whether they need a document for a future tax declaration, a lawyer, a bank, an insurance company or a property sale, everything can be stored and accessed from one account.”

EasySpanishTax.com is aimed at holiday home owners, second-home owners, retirees, investors and landlords who own property in Spain but live abroad. The platform is especially useful for owners in the UK, Ireland, Sweden, Norway, Denmark, Germany, France, Belgium, the Netherlands and other countries with a high number of Spanish property owners.

The company’s mission is to make Spanish property administration easier for non-residents by combining simple online tax filing with practical document management.

“Owning a property in Spain should be enjoyable,” says Ingbrant. “Tax filing and paperwork should not be a source of stress. EasySpanishTax.com is designed to give owners a simple, affordable and reliable way to stay organised and compliant.”

About EasySpanishTax.com

EasySpanishTax.com is an online platform created for non-resident property owners in Spain. The website helps users prepare and file Modelo 210 tax declarations through a simple do-it-yourself process. The users can also store and manage important property-related documents in their personal account, making EasySpanishTax.com a practical administration hub for Spanish property owners living abroad.

The platform is owned by the real estate company Enova Estates S.L. in Manilva, Costa del Sol, Spain.

Contact:
Enova Estates SL
Björn Ingbrant
***@enovaestates.com

Photo(s):
https://www.prlog.org/13153344

Press release distributed by PRLog

View original content:https://www.prnewswire.com/news-releases/easyspanishtaxcom-launches-simple-diy-modelo-210-filing-solution-for-non-resident-property-owners-in-spain-302805652.html

SOURCE Enova Estates

Continue Reading

Trending